In a regulatory filing on September 9, 2026, BOAN BIOTECH (06955) announced that it had repurchased 1 million of its own shares on the same day.
The share buyback was executed at a total cost of HK$2.922 million, reflecting the company's ongoing capital management initiatives.
The repurchase activity underscores BOAN BIOTECH's commitment to enhancing shareholder value amid prevailing market conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.